Pulmonary tuberculosis (TB) caused by Mycobacterium tuberculosis (M.tb) is the leading cause of infectious disease-related death worldwide. The critical role of adaptive immunity in anti-TB host defence has been firmly established; thus, current efforts in developing novel vaccination strategies against TB are primarily focused on generating protective adaptive immunity at the infection site, the lungs. Innate immunity has not been a target for vaccination strategies against TB due to the belief that innate immune cells cannot exhibit memory-like characteristics which are known to be central to the long-lasting immunity created by vaccines. Also, the importance of innate immunity in anti-TB immunity has been overlooked. However, over 25% of individuals that are heavily exposed to M.tb clear infection without any detectable conventional T cell immune responses, suggesting a crucial role for innate immune cells in bacterial clearance. Interestingly, the early protection in these individuals is associated with their Bacillus Calmette-Guerin (BCG) vaccination status. Epidemiological studies have shown that BCG is capable of providing protection against numerous infections unrelated to TB in an innate-immune dependent manner. Such observations suggest that the innate immune system exhibits memory-like characteristics, capable of remembering the exposure to the vaccine and thereby responding in an augmented manner to future systemic infections. Nonetheless, it still remains unknown whether parenteral BCG immunization modulates the innate immune cells in the lung and airways, and if so, what role the trained innate immune cells play in early protection against pulmonary TB. Using a subcutaneous BCG immunization and pulmonary TB challenge murine model, we show that early protection against M.tb is independent of adaptive responses in the BCG immunized host. Our data suggest that enhanced early protection is mediated by the BCG-trained memory alveolar macrophages that we have shown to be functionally, phenotypically, metabolically, and transcriptionally altered following immunization. These novel findings suggest a significant anti-TB immune role for the innate immune memory established in the lung following parenteral BCG immunization and have important implications for the development of novel vaccination strategies against TB. / Thesis / Master of Science (MSc) / Pulmonary tuberculosis (TB) is a disease of the lung and is now one of the leading causes of human mortality worldwide. For more than eight decades, parenterally administered Bacillus Calmette–Guérin (BCG) vaccine has been globally used as the only approved vaccine against TB. Recently, it has also been observed that BCG vaccination provides protection against other diseases unrelated to TB and reduces childhood mortality in many developing countries where it is routinely administered to children shortly after birth. The mechanisms underlying the off-target protective effects of BCG vaccine remains largely under-investigated. In this project, we investigated how BCG vaccination enhances the immune system responses against TB and other unrelated infectious diseases. A better understanding of how the BCG vaccination modulates our immune system will provide us with the knowledge that will be useful in the development of more effective vaccination strategies against infectious diseases.

O Histoplasma capsulatum é um fungo dimórfico, patogênico e responsável por graves lesões pulmonares. A infecção é adquirida pela inalação de conídios e posterior conversão para leveduras nos alvéolos e bronquíolos, onde são fagocitadas por macrófagos alveolares residentes e leucócitos que migram para o local da infecção. Recentemente, demonstramos que animais infectados com H. capsulatum e tratados com inibidor da síntese de prostaglandinas apresentaram diminuição de carga fúngica nos pulmões e baço, aumento da produção de nitrito e da fagocitose de leveduras por macrófagos alveolares, e maior sobrevivência, quando comparados com os animais somente infectados. Porém, neste estudo não foram determinados quais subtipos de prostaglandinas participam na patogênese da histoplasmose. Vários grupos de pesquisa têm demonstrado que PGD2 e PGE2 podem ter ações biológicas distintas quanto à remoção de microrganismos no hospedeiro. Desta maneira, é fundamental o entendimento do papel da PGD2 e da PGE2 nos mecanismos efetores dos macrófagos na defesa do hospedeiro, especialmente na histoplasmose. Portanto, o objetivo deste estudo foi investigar a participação da PGD2 e PGE2 na infecção experimental por H. capsulatum. Assim, demonstramos que a PGD2 aumentou a fagocitose e mecanismos microbicidas de macrófagos alveolares infectados in vitro com H. capsulatum. Observamos ainda que a 15dPGJ2, metabólito da PGD2, aumentou somente a fagocitose, e PGE2 inibiu os mecanismos efetores do macrófago. Mostramos ainda o aumento de BLT1 em macrófagos alveolares após adição de PGD2, e a possível ligação desta ao BLT1, e de LTB4 em DP2. Além disso, caracterizamos micropartículas de PLGA contendo PGD2 (MS-PGD2), e investigamos seus efeitos. O tamanho, carga elétrica e morfologia das micropartículas foram adequados para um tratamento intranasal e para fagocitose por macrófagos alveolares. As MS-PGD2 foram fagocitadas e capazes de ativar NF-B, e consequentemente, influenciar na produção de nitrito, IL-1, TNF-, IL-6 e TGF-. Com base nestes dados, avaliamos os efeitos do tratamento da MS-PGD2 ou da MS-PGE2 em animais infectados com H. capsulatum. Estas foram administradas via intranasal em animais infectados e tratados ou não com celecoxibe. Verificamos a diminuição da carga fúngica nos pulmões e baço, diminuição do infiltrador celular no espaço broncoalveolar e de citocinas inflamatórias no pulmão após tratamento com MS-PGD2. Contrariamente, após tratamento da MS-PGE2 observamos maior carga fúngica nos pulmões e baço, e aumento da inflamação no tecido e maior produção de IL-10. Além disso, demonstramos que no 21° dia após infecção, referente ao 7° dia após o término do tratamento com MS-PGD2, a carga fúngica manteve-se reduzida nos pulmões, comprovando assim a eficácia deste tratamento. Posteriormente, utilizando inibidores específicos, HQL-79 e CAY10526, mostramos respectivamente o papel protetor da PGD2 e o deletério da PGE2 na histoplasmose. Em conjunto, nossos dados contribuíram para o entendimento das funções antagônicas da PGD2 e PGE2 nesta micose. / Histoplasma capsulatum is a pathogenic dimorphic fungus and responsible for severe pulmonary lesions. Infection is acquired by inhalation of conidia and posterior conversion to yeasts in the alveoli and bronchioles, in which they are phagocyted by resident alveolar macrophages and leukocytes that migrate to the local infection. Recently, we demonstrate that mice infected by H. capsulatum and treated with inhibitor of prostaglandins synthesis presented a decrease in fungal burden in lungs and spleen, increase in nitrite production and uptake of yeasts by alveolar macrophages, and more survival, when compared with animals only infected. However, in this study, it was not determined what subtypes of prostaglandins participate in pathogenesis of histoplasmosis. Many research groups have demonstrated that PGD2 and PGE2 can have different biological effects regarding to microorganisms elimination in the host. Thus, it is primordial the understanding about the role of PGD2 and PGE2 on effector mechanisms of macrophages in host defense, especially in histoplasmosis. Therefore, the aim of this study was to investigate the role of PGD2 and PGE2 on experimental infection by H. capsulatum. So, we verify that PGD2 increased the uptake and microbicidal mechanisms of alveolar macrophages infected in vitro by H. capsulatum. 15dPGJ2, a PGD2 metabolite, increased only the phagocytosis, and PGE2 inhibited the effector mechanisms of macrophages. Among these results, we showed an increase of BLT1 expression on alveolar macrophages after addition of PGD2, and a possible binding of this mediator to BLT1, and of LTB4 to DP2. Later, as tool of therapeutic investigation, we used PGD2 encapsulation in biodegradable polymer, PLGA, in order to preserve its stability. Size, zeta potential and morphology were adequate for a possible intranasal treatment and uptake by alveolar macrophages. MS-PGD2 were phagocyted and able to activate NF-B, and consequently, to modulate nitrite, IL-1, TNF-, IL-6 and TGF- production. In this context, we purpose a treatment of the infection with MS-PGD2, in comparison to treatment with PGE2. MS-PGD2 were administrated via intranasal in infected mice, treated or not with celecoxib. We verify a decrease of fungal burden in lungs and spleen, less cellular infiltrate and decrease of some inflammatory cytokines. In contrast, after treatment of MS-PGE2, we observed greater fungal burden in the lungs and spleen, and an increase of the tissue inflammation and production of IL-10. Furthermore, we show that on day 21 after infection, referring to the 7th day after the treatment with MS-PGD2, fungal burden remained reduced in the lungs, thus proving the effectiveness of the treatment. Subsequently, using specific inhibitors, HQL-79 and CAY10526, respectively show the protective role of PGD2 and in deleterious to PGE2 in histoplasmosis. Together, our data contribute to the understanding of the antagonistic functions of PGD2 and PGE2 in this mycosis.

Thesis (Ph.D. in Toxicology) -- University of Colorado Denver, 2008. / Typescript. Includes bibliographical references (leaves 224-253). Free to UCD Anschutz Medical Campus. Online version available via ProQuest Digital Dissertations;

O Histoplasma capsulatum é um fungo dimórfico, patogênico e responsável por graves lesões pulmonares. A infecção é adquirida pela inalação de conídios e posterior conversão para leveduras nos alvéolos e bronquíolos, onde são fagocitadas por macrófagos alveolares residentes e leucócitos que migram para o local da infecção. Recentemente, demonstramos que animais infectados com H. capsulatum e tratados com inibidor da síntese de prostaglandinas apresentaram diminuição de carga fúngica nos pulmões e baço, aumento da produção de nitrito e da fagocitose de leveduras por macrófagos alveolares, e maior sobrevivência, quando comparados com os animais somente infectados. Porém, neste estudo não foram determinados quais subtipos de prostaglandinas participam na patogênese da histoplasmose. Vários grupos de pesquisa têm demonstrado que PGD2 e PGE2 podem ter ações biológicas distintas quanto à remoção de microrganismos no hospedeiro. Desta maneira, é fundamental o entendimento do papel da PGD2 e da PGE2 nos mecanismos efetores dos macrófagos na defesa do hospedeiro, especialmente na histoplasmose. Portanto, o objetivo deste estudo foi investigar a participação da PGD2 e PGE2 na infecção experimental por H. capsulatum. Assim, demonstramos que a PGD2 aumentou a fagocitose e mecanismos microbicidas de macrófagos alveolares infectados in vitro com H. capsulatum. Observamos ainda que a 15dPGJ2, metabólito da PGD2, aumentou somente a fagocitose, e PGE2 inibiu os mecanismos efetores do macrófago. Mostramos ainda o aumento de BLT1 em macrófagos alveolares após adição de PGD2, e a possível ligação desta ao BLT1, e de LTB4 em DP2. Além disso, caracterizamos micropartículas de PLGA contendo PGD2 (MS-PGD2), e investigamos seus efeitos. O tamanho, carga elétrica e morfologia das micropartículas foram adequados para um tratamento intranasal e para fagocitose por macrófagos alveolares. As MS-PGD2 foram fagocitadas e capazes de ativar NF-B, e consequentemente, influenciar na produção de nitrito, IL-1, TNF-, IL-6 e TGF-. Com base nestes dados, avaliamos os efeitos do tratamento da MS-PGD2 ou da MS-PGE2 em animais infectados com H. capsulatum. Estas foram administradas via intranasal em animais infectados e tratados ou não com celecoxibe. Verificamos a diminuição da carga fúngica nos pulmões e baço, diminuição do infiltrador celular no espaço broncoalveolar e de citocinas inflamatórias no pulmão após tratamento com MS-PGD2. Contrariamente, após tratamento da MS-PGE2 observamos maior carga fúngica nos pulmões e baço, e aumento da inflamação no tecido e maior produção de IL-10. Além disso, demonstramos que no 21° dia após infecção, referente ao 7° dia após o término do tratamento com MS-PGD2, a carga fúngica manteve-se reduzida nos pulmões, comprovando assim a eficácia deste tratamento. Posteriormente, utilizando inibidores específicos, HQL-79 e CAY10526, mostramos respectivamente o papel protetor da PGD2 e o deletério da PGE2 na histoplasmose. Em conjunto, nossos dados contribuíram para o entendimento das funções antagônicas da PGD2 e PGE2 nesta micose. / Histoplasma capsulatum is a pathogenic dimorphic fungus and responsible for severe pulmonary lesions. Infection is acquired by inhalation of conidia and posterior conversion to yeasts in the alveoli and bronchioles, in which they are phagocyted by resident alveolar macrophages and leukocytes that migrate to the local infection. Recently, we demonstrate that mice infected by H. capsulatum and treated with inhibitor of prostaglandins synthesis presented a decrease in fungal burden in lungs and spleen, increase in nitrite production and uptake of yeasts by alveolar macrophages, and more survival, when compared with animals only infected. However, in this study, it was not determined what subtypes of prostaglandins participate in pathogenesis of histoplasmosis. Many research groups have demonstrated that PGD2 and PGE2 can have different biological effects regarding to microorganisms elimination in the host. Thus, it is primordial the understanding about the role of PGD2 and PGE2 on effector mechanisms of macrophages in host defense, especially in histoplasmosis. Therefore, the aim of this study was to investigate the role of PGD2 and PGE2 on experimental infection by H. capsulatum. So, we verify that PGD2 increased the uptake and microbicidal mechanisms of alveolar macrophages infected in vitro by H. capsulatum. 15dPGJ2, a PGD2 metabolite, increased only the phagocytosis, and PGE2 inhibited the effector mechanisms of macrophages. Among these results, we showed an increase of BLT1 expression on alveolar macrophages after addition of PGD2, and a possible binding of this mediator to BLT1, and of LTB4 to DP2. Later, as tool of therapeutic investigation, we used PGD2 encapsulation in biodegradable polymer, PLGA, in order to preserve its stability. Size, zeta potential and morphology were adequate for a possible intranasal treatment and uptake by alveolar macrophages. MS-PGD2 were phagocyted and able to activate NF-B, and consequently, to modulate nitrite, IL-1, TNF-, IL-6 and TGF- production. In this context, we purpose a treatment of the infection with MS-PGD2, in comparison to treatment with PGE2. MS-PGD2 were administrated via intranasal in infected mice, treated or not with celecoxib. We verify a decrease of fungal burden in lungs and spleen, less cellular infiltrate and decrease of some inflammatory cytokines. In contrast, after treatment of MS-PGE2, we observed greater fungal burden in the lungs and spleen, and an increase of the tissue inflammation and production of IL-10. Furthermore, we show that on day 21 after infection, referring to the 7th day after the treatment with MS-PGD2, fungal burden remained reduced in the lungs, thus proving the effectiveness of the treatment. Subsequently, using specific inhibitors, HQL-79 and CAY10526, respectively show the protective role of PGD2 and in deleterious to PGE2 in histoplasmosis. Together, our data contribute to the understanding of the antagonistic functions of PGD2 and PGE2 in this mycosis.

No description available.

Introdução Os fumantes inalam grandes quantidades de partículas de carbono, o que pode contribuir para efeitos adversos pulmonares e sistêmicos. É sabido que os macrófagos alveolares (MA) desempenham um papel extremamente importante no reconhecimento e processamento de qualquer material estranho inalado e são as células predominantes que processam e removem partículas inaladas. Existe também a deposição superficial a longo prazo do carbono observado nos pulmões de fumantes em autópsias. Atualmente, a distribuição e retenção de partículas de fumo derivadas de cigarros quando a pessoa também está exposta a níveis elevados de poluição do ar ainda não é clara. Portanto, procurou-se avaliar a carga de carbono nos MA e a deposição de superfície pulmonar em uma população exposta a alta poluição atmosférica (São Paulo), tanto em fumantes como não-fumantes. Métodos Uma coorte de 72 sujeitos post mortem foi obtida do Serviço de Verificação de Óbitos da Capital da Universidade de São Paulo (SVOC). As imagens das superfícies pulmonares foram obtidas sob condições padrão e pequenos fragmentos de tecido pulmonar foram coletados para análise de macrófagos usando a técnica de esfregaço. A superfície total de negro de carbono foi analisada utilizando o programa Imagem J (National Institute of Health, MD, EUA), teste cego ao fumo. A absorção interna de carbono nos MA foi medida utilizando o programa Image Pro Plus (The Proven Solution, Media Cybernetics Inc., EUA). A aprovação ética foi obtida. A média de negro de carbono de macrófagos tanto em fumantes como em não-fumantes foi analisada utilizando teste de Mann Whitney e expressa como intervalo interquartil (IQR). Resultados Os fumantes têm um nível significativamente mais elevado de negro de carbono nos macrófagos alveolares (103.4 (IQR 29.44 to 226.3) vs. 9.27 (IQR 3.1 to 85.13) um2, P < 0.001)103.4um2. Não houve diferença significativa entre a área média de deposição superficial de carbono nos pulmões de fumantes e não fumantes de 6, 74 cm2 (IQR 3, 47 a 10, 02) versus 5, 20 cm2 (IQR 2, 29 a 7, 54) P=NS. Conclusão O teor de carbono nos MA é claramente muito maior nos fumantes do que os nãofumantes. No entanto, a análise da superfície pulmonar não mostrou diferença significativa. Isso pode indicar que, em uma área de alta poluição do ar, o principal fator que contribui para a deposição de carbono no pulmão a longo prazo é a exposição à poluição com efeitos limitados da exposição à fumaça de cigarro. O preto de carbono nos MA ainda aparece significativamente influenciado pela exposição à fumaça de cigarro / Rationale Smokers inhale large amounts of carbonaceous particulate matter, which may contribute to pulmonary and systemic adverse effects. It is clear that alveolar macrophages (AM) play a critically important role in the recognition and processing of any inhaled foreign material and are the predominant cells that process and remove inhaled particulate matter from the lung. There is also long-term surface deposition of carbon seen in the lungs of smokers at post-mortem. At present the distribution and retention of cigarette smoke-derived particulate matter when the person is also exposed to high levels of background air pollution is unclear. Therefore we sought to assess both AM carbon loading and lung surface deposition in a population exposed to high background air pollution (São Paulo) in both smokers and non-smokers. Methods A cohort of 72 post-mortem subjects was obtained from São Paulo Autopsy Centre (SVOC). Images of lung surfaces were obtained under standard conditions and small fragments of lung tissue were collected for macrophage analysis using smear technique. The total surface black carbon was analysed using Image J (National Institute of Health, MD, USA), blinded to smoking status. Internal AM carbon uptake was measured using Image Pro Plus (The Proven Solution, Media Cybernetics Inc., USA). Ethical approval was obtained. Mean macrophage black carbon in both smokers and non-smokers was analysed using Mann Whitney and expressed as median (IQR). Results Smokers have a significantly higher level of mean macrophage black carbon (103.4 (IQR 29.44 to 226.3) vs. 9.27 (IQR 3.1 to 85.13) um2, P < 0.001)103.4um2. There was no significant difference between the mean area of surface deposition of carbon in the lungs of smokers and non-smokers 6.74 cm2 (IQR 3.47 to 10.02) versus 5.20cm2 (IQR 2.29 to 7.54) P=NS. Conclusion AM carbon content is clearly much higher in the smokers than the non-smokers. However the lung surface analysis showed no significant difference. This could indicate that in an area of high air pollution the main contributing factor to long term lung carbon deposition is pollution exposure with limited effects from cigarette smoke exposure. AM black carbon still appears significantly influenced by cigarette smoke exposure

Introdução Os fumantes inalam grandes quantidades de partículas de carbono, o que pode contribuir para efeitos adversos pulmonares e sistêmicos. É sabido que os macrófagos alveolares (MA) desempenham um papel extremamente importante no reconhecimento e processamento de qualquer material estranho inalado e são as células predominantes que processam e removem partículas inaladas. Existe também a deposição superficial a longo prazo do carbono observado nos pulmões de fumantes em autópsias. Atualmente, a distribuição e retenção de partículas de fumo derivadas de cigarros quando a pessoa também está exposta a níveis elevados de poluição do ar ainda não é clara. Portanto, procurou-se avaliar a carga de carbono nos MA e a deposição de superfície pulmonar em uma população exposta a alta poluição atmosférica (São Paulo), tanto em fumantes como não-fumantes. Métodos Uma coorte de 72 sujeitos post mortem foi obtida do Serviço de Verificação de Óbitos da Capital da Universidade de São Paulo (SVOC). As imagens das superfícies pulmonares foram obtidas sob condições padrão e pequenos fragmentos de tecido pulmonar foram coletados para análise de macrófagos usando a técnica de esfregaço. A superfície total de negro de carbono foi analisada utilizando o programa Imagem J (National Institute of Health, MD, EUA), teste cego ao fumo. A absorção interna de carbono nos MA foi medida utilizando o programa Image Pro Plus (The Proven Solution, Media Cybernetics Inc., EUA). A aprovação ética foi obtida. A média de negro de carbono de macrófagos tanto em fumantes como em não-fumantes foi analisada utilizando teste de Mann Whitney e expressa como intervalo interquartil (IQR). Resultados Os fumantes têm um nível significativamente mais elevado de negro de carbono nos macrófagos alveolares (103.4 (IQR 29.44 to 226.3) vs. 9.27 (IQR 3.1 to 85.13) um2, P < 0.001)103.4um2. Não houve diferença significativa entre a área média de deposição superficial de carbono nos pulmões de fumantes e não fumantes de 6, 74 cm2 (IQR 3, 47 a 10, 02) versus 5, 20 cm2 (IQR 2, 29 a 7, 54) P=NS. Conclusão O teor de carbono nos MA é claramente muito maior nos fumantes do que os nãofumantes. No entanto, a análise da superfície pulmonar não mostrou diferença significativa. Isso pode indicar que, em uma área de alta poluição do ar, o principal fator que contribui para a deposição de carbono no pulmão a longo prazo é a exposição à poluição com efeitos limitados da exposição à fumaça de cigarro. O preto de carbono nos MA ainda aparece significativamente influenciado pela exposição à fumaça de cigarro / Rationale Smokers inhale large amounts of carbonaceous particulate matter, which may contribute to pulmonary and systemic adverse effects. It is clear that alveolar macrophages (AM) play a critically important role in the recognition and processing of any inhaled foreign material and are the predominant cells that process and remove inhaled particulate matter from the lung. There is also long-term surface deposition of carbon seen in the lungs of smokers at post-mortem. At present the distribution and retention of cigarette smoke-derived particulate matter when the person is also exposed to high levels of background air pollution is unclear. Therefore we sought to assess both AM carbon loading and lung surface deposition in a population exposed to high background air pollution (São Paulo) in both smokers and non-smokers. Methods A cohort of 72 post-mortem subjects was obtained from São Paulo Autopsy Centre (SVOC). Images of lung surfaces were obtained under standard conditions and small fragments of lung tissue were collected for macrophage analysis using smear technique. The total surface black carbon was analysed using Image J (National Institute of Health, MD, USA), blinded to smoking status. Internal AM carbon uptake was measured using Image Pro Plus (The Proven Solution, Media Cybernetics Inc., USA). Ethical approval was obtained. Mean macrophage black carbon in both smokers and non-smokers was analysed using Mann Whitney and expressed as median (IQR). Results Smokers have a significantly higher level of mean macrophage black carbon (103.4 (IQR 29.44 to 226.3) vs. 9.27 (IQR 3.1 to 85.13) um2, P < 0.001)103.4um2. There was no significant difference between the mean area of surface deposition of carbon in the lungs of smokers and non-smokers 6.74 cm2 (IQR 3.47 to 10.02) versus 5.20cm2 (IQR 2.29 to 7.54) P=NS. Conclusion AM carbon content is clearly much higher in the smokers than the non-smokers. However the lung surface analysis showed no significant difference. This could indicate that in an area of high air pollution the main contributing factor to long term lung carbon deposition is pollution exposure with limited effects from cigarette smoke exposure. AM black carbon still appears significantly influenced by cigarette smoke exposure

The innate immune protein surfactant protein (SP-) D is a carbohydrate binding protein that was originally isolated from mucosal lung tissues. Recently, studies show that SP-D binds to antibodies, including immunoglobulin M (IgM), which interacts with late apoptotic cells. Here we focus on the interaction between SP-D and IgM as they pertain to late apoptotic cell clearance. We hypothesized that the three-way interaction between IgM, SP-D and late apoptotic cells is functionally applicable to clearing late apoptotic cells from the lungs, thereby reducing lung inflammation. We show that SP-D binds to IgM and that IgM binds to the late apoptotic subclass of dying cells. We demonstrate that IgM and SP-D can both bind to late apoptotic cells in mutually distinct regions while also displaying some regional overlap. We show evidence that during LPS-induced lung inflammation both IgM and SP-D levels are elevated and this corresponds to an augmentation of apoptotic cell clearance. We illustrate that the protein interaction of IgM and SP-D is functionally relevant to apoptotic cell clearance in the lungs by showing that late apoptotic cells coated in IgM and/or SP-D are cleared more efficiently than control cells, by alveolar macrophages in vivo. Our ex vivo studies further show that these cells internalize apoptotic cells by engulfing very small particles released from the dying cells. We then showed that IgM preferentially directs the engulfment of small particles (~1 μm) by macrophages, in an apparent size-specific antibody-dependent particle clearance function. Our data reveals a novel relationship amongst IgM, SP-D, apoptotic cells, and alveolar macrophages that contributes to our understanding of apoptotic cell clearance, which may be used in the future to generate strategies addressing apoptotic cell accumulation or clearance deficiency in disease.

The innate immune protein surfactant protein (SP-) D is a carbohydrate binding protein that was originally isolated from mucosal lung tissues. Recently, studies show that SP-D binds to antibodies, including immunoglobulin M (IgM), which interacts with late apoptotic cells. Here we focus on the interaction between SP-D and IgM as they pertain to late apoptotic cell clearance. We hypothesized that the three-way interaction between IgM, SP-D and late apoptotic cells is functionally applicable to clearing late apoptotic cells from the lungs, thereby reducing lung inflammation. We show that SP-D binds to IgM and that IgM binds to the late apoptotic subclass of dying cells. We demonstrate that IgM and SP-D can both bind to late apoptotic cells in mutually distinct regions while also displaying some regional overlap. We show evidence that during LPS-induced lung inflammation both IgM and SP-D levels are elevated and this corresponds to an augmentation of apoptotic cell clearance. We illustrate that the protein interaction of IgM and SP-D is functionally relevant to apoptotic cell clearance in the lungs by showing that late apoptotic cells coated in IgM and/or SP-D are cleared more efficiently than control cells, by alveolar macrophages in vivo. Our ex vivo studies further show that these cells internalize apoptotic cells by engulfing very small particles released from the dying cells. We then showed that IgM preferentially directs the engulfment of small particles (~1 μm) by macrophages, in an apparent size-specific antibody-dependent particle clearance function. Our data reveals a novel relationship amongst IgM, SP-D, apoptotic cells, and alveolar macrophages that contributes to our understanding of apoptotic cell clearance, which may be used in the future to generate strategies addressing apoptotic cell accumulation or clearance deficiency in disease.

No description available.